Because of their glucose lowering effects, therapies that enhance incretin actions through inhibiting degradation of endogenous incretins or through activation of the GLP-1 receptor are now in use for the treatment of type 2 diabetes. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.